The treatment of Ankylosin Spondylitis by Bushenqiangduqinghuatang: A randomized controlled clinical trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100052323

Enrollment

Unknown

Registered

2021-10-24

Start date

2021-10-28

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ankylosing spondylitis

Interventions

treatment group:Bushenqiangduqinghuatang and celecoxib

Control group :celecoxib

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged > 16 years; 2. Meet the diagnostic criteria of Western medicine for active AS; 3. Meet the diagnostic criteria of TCM kidney deficiency and damp-heat type large crotch; 4. Voluntarily sign the informed consent; 5. Drug elution: Non-steroidal anti-inflammatory drugs (NSAIDs) have been used, and the group can only be enrolled after 2 weeks of drug withdrawal; sulfasalazine (SASP), methotrexate (MTX), Arovia (LEF) ) and glucocorticoids, they can only be enrolled after 1 month of drug withdrawal; those who use biological agents can only be enrolled after 3 months of drug withdrawal.

Exclusion criteria

Exclusion criteria: 1. Pregnant or breastfeeding women and mentally ill patients, with severe malnutrition, or with severe damage to the heart, brain, kidney, and hematopoietic system; 2. Patients with other seronegative spondyloarthropathy or other rheumatic diseases; 3. Late-stage bamboo-like degeneration of the spine; 4. Those who are allergic to sulfonamides.

Design outcomes

Primary

Measure	Time frame
Inflammatory indicators;ossification factor;Drug safety indicators;	—

Countries

China

Contacts

Public ContactKong Weiping

China-Japan Friendship Hospital

kongweiping75@126.com+86 13611038252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026